Gulf Pharmaceutical Industries P.S.C.

ADX:JULPHAR Stock Report

Market Cap: د.إ1.4b

Gulf Pharmaceutical Industries P.S.C Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Basel Nimer Ziyadeh

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure3yrs
CEO ownershipn/a
Management average tenure3.1yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Screens Well But There Might Be A Catch

Apr 28
Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Screens Well But There Might Be A Catch

Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are

Mar 25
Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are

Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified

Oct 16
Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Jan 15
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Nov 04
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Mar 26
Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

Feb 08
Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

Dec 14
Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

CEO

Basel Nimer Ziyadeh

3yrs
Tenure

Mr. Basel Nimer Ali Ziyadeh is Chief Executive Officer of Gulf Pharmaceutical Industries P.S.C. from February 2023. Mr. Basel was CEO for Tabuk Pharmaceuticals, where he was instrumental in transforming th...

Leadership Team

NamePositionTenureCompensationOwnership
Basel Nimer Ziyadeh
Chief Executive Officer3yrsno datano data
Khalid Malkawi
Chief Financial Officer2.1yrsno datano data
Malik Metahri
Chief Technical Officer3.1yrsno datano data
Hessa Alshehhi
Investor Relations Management Officerno datano datano data
Adel Khalaf
General Counsel & Chief Compliance Officer6.1yrsno datano data
Ahmed Al Khatib
Director of PR & Communicationsno datano datano data
Juergen Lauterbach
Chief Corporate Development & Strategy Officer3.5yrsno datano data
Gopa Kumar
Chief Human Resources Officer6.1yrsno datano data
Alaa El Gamal
Chief Commercial Officer2.1yrsno datano data
Rayan Omer
Company Secretaryno datano datano data
3.1yrs
Average Tenure

Experienced Management: JULPHAR's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Abdulaziz Al Zaabi
Director9.1yrsno datano data
Taghreed Al-Shunnar
Director1.1yrsno datano data
Raman Garg
Independent Director5.9yrsno datano data
Jean Diab
Vice-Chairman of the Board2.8yrsno datano data
Saqer Bin Al Qassimi
Chairman of the Board21.1yrsno datano data
Medhat Mohamed Al Gamal
Director7.1yrsno datano data
Olfa Gam
Director4.5yrsno datano data
Hamodi Abas Al limy
Director3.7yrsno datano data
Vinod Nagappan
Directorless than a yearno datano data
4.5yrs
Average Tenure
61yo
Average Age

Experienced Board: JULPHAR's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/16 21:21
End of Day Share Price 2026/02/16 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gulf Pharmaceutical Industries P.S.C. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kais KriaaAlphaMena
Rim Ben Salah GharbiAlphaMena
null RESEARCH DEPARTMENTPrime Research